Logo

Compugen and Diagnostic Products to Co-Develop Diagnostics

Sep 08, 2004

NEW YORK, Sept. 8 (GenomeWeb News) - Compugen and Diagnostic Products plan to co-develop diagnostics based on Compugen's biomarkers, the companies said today.

 

Under the agreement, Diagnostic Products, of Los Angeles, plans to develop immunoassay- or nucleic acid-based diagnostics using potential biomarkers provided by Compugen. The companies want to focus on cancer and cardiovascular diseases.

 

Compugen, of Tel Aviv, is entitled to milestone payments as well as royalties on the sales of any diagnostic products. Compugen also has the right to develop any biomarkers for therapeutic purposes.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.